Geode Capital Management LLC raised its stake in Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report) by 3.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,929,716 shares of the company’s stock after buying an additional 321,395 shares during the period. Geode Capital Management LLC’s holdings in Zomedica were worth $1,363,000 at the end of the most recent quarter.
Separately, Jane Street Group LLC purchased a new stake in Zomedica in the 3rd quarter worth approximately $25,000. Hedge funds and other institutional investors own 8.95% of the company’s stock.
Zomedica Stock Down 2.2 %
Shares of Zomedica stock opened at $0.14 on Friday. Zomedica Corp. has a 12 month low of $0.12 and a 12 month high of $0.20. The firm has a market cap of $135.43 million, a price-to-earnings ratio of -2.30 and a beta of 1.04.
Analyst Ratings Changes
Check Out Our Latest Report on Zomedica
Zomedica Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
See Also
- Five stocks we like better than Zomedica
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to Use the MarketBeat Stock Screener
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Want to see what other hedge funds are holding ZOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report).
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.